))
NHS’s Cybersecurity Problem, A Win for Psilocybin Research
Manage episode 418505821 series 3046075
Content provided by Vynamic. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Vynamic or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this Trending News Europe episode, Jack, Jen, and Ollie discuss a few recent newsworthy items, including an increase in cyberattacks on the healthcare sector, Europe’s plan to future-proof its Biotech Sector and New Research from the University of Oxford into psilocybin as a potential treatment for depression.
Podcast Tags: healthcare, healthcare news, life sciences, NHS, cybersecurity, biotech, research & development, pharmaceuticals, depression, psilocybin, mental health, psychedelics, mental health awareness week
Source Links:
- ’Large volume’ of data stolen from NHS Dumfries and Galloway published on dark web
- Huge volume of NHS patient and staff data released by hacker
- NHS cyber attack: Why stolen medical information is so much more valuable than financial data
- Cyber attacks are one of the biggest threats facing healthcare systems
- Government Launches NHS Cyber Security Strategy
- US tech group Palantir wins lucrative NHS data contract
- Patient privacy fears as US spy tech firm Palantir wins £330m NHS contract
- European Commission lays down path to future-proof EU biotechnology
- Roche to buy Carmot for up to $3.1bn as race for obesity drugs intensifies
- Roche agrees $7.1bn deal for Telavant to boost drug pipeline
- Europe’s biotech innovation in the balance
- Commission takes action to boost biotechnology and biomanufacturing in the EU
- Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
- EU launches landmark €6.5M study on use of psychedelics to treat mental disorders
- Magic mushrooms’ psilocybin can alleviate severe depression when used with therapy
- Psychedelic drug research held back by UK rules and attitudes, say scientists
- King’s College Psychoactive Trials Group
Panel – Jack Young, Jen Burke, Ollie May
Research & Production – Karan Pandya, Jack Young
Recording & Editing – Mike Liberto, Rachel Skonecki
For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.
184 episodes
Share
